Palleon Pharmaceuticals to Present First-in-Class B7-H3-Targeted Sialidase HLX316/E-688 at AACR 2026
核心洞察
Palleon Pharmaceuticals (搜索) will present data on HLX316/E-688 (搜索), a first-in-class B7-H3 (搜索)-targeted sialidase designed to enhance innate and adaptive anti-tumor immunity at the 2026 AACR Annual Meeting.
The investigational treatment is developed from Palleon's EAGLE Platform and addresses immune evasion mechanisms by enhancing desialylation of tumor cells expressing B7-H3 (搜索).
Shanghai Henlius Biotech (搜索) has received NMPA clearance for a Phase 1 clinical trial of HLX316/E-688 (搜索) in China for advanced or metastatic solid tumors (搜索).
Palleon Pharmaceuticals (搜索) will showcase its first-in-class B7-H3 (搜索)-targeted sialidase HLX316/E-688 (搜索) at the 2026 American Association for Cancer Research (搜索) (AACR) Annual Meeting in San Diego, scheduled for April 17-22. The company will deliver an oral presentation during the "New Drugs on the Horizon" series on April 19 and present a poster on April 22.
Novel Mechanism Targets Immune Evasion
HLX316/E-688 (搜索) represents a breakthrough approach developed from Palleon's EAGLE (Enzyme-Antibody Glycan-Editing) Platform. The investigational treatment is designed to address key mechanisms of immune evasion by enhancing the desialylation of tumor cells that express B7-H3 (搜索), helping to restore both innate and adaptive anti-tumor responses in the tumor microenvironment.
The therapy targets excessive sialic acid on tumor cell surfaces, a mechanism that allows cancer (搜索) cells to evade immune recognition. By removing this protective coating, HLX316/E-688 (搜索) aims to expose pathogenic cells to immune clearance while reprogramming immune responses.
Clinical Development in China
Shanghai Henlius Biotech (搜索) is developing HLX316/E-688 (搜索) in China and has received clearance from the China National Medical Products Administration (搜索) (NMPA) for an Investigational New Drug (IND) application. The approved Phase 1 clinical trial will evaluate the treatment in patients with advanced or metastatic solid tumors (搜索).
AACR Presentation Details
The presentations will be titled "A First-in-Class Human Sialidase-Armed Anti-B7-H3 (搜索) Antibody that Enhances Innate and Adaptive Antitumor Immune Responses" (Abstract ID: 7158). The oral presentation is scheduled for Sunday, April 19 from 3:00 PM to 4:30 PM PT, while the poster session will take place Wednesday, April 22 from 9:00 AM to 12:00 PM PT.
Both presentations fall under the "Experimental and Molecular Therapeutics" category, specifically within the session titled "Overcoming Microenvironmental and Delivery Barriers in Cancer (搜索) Therapy."
Company Background
Palleon Pharmaceuticals (搜索) is a clinical-stage biotherapeutics company focused on developing engineered enzyme therapies that remove excessive sialic acid to treat both cancer (搜索) and autoimmune diseases (搜索). The company was co-founded based on the glycobiology research of Carolyn Bertozzi, winner of the 2022 Nobel Prize in Chemistry, and represents the first company to translate this foundational science into human therapeutics targeting cell surface glycans to alter immune recognition.
The presentations will be made available on the Glycobiology Education section of Palleon Pharmaceuticals (搜索)' website following the conference.